Zydus Lifesciences Limited has published its Integrated Annual Report for the financial year ended March 31, 2026, marking the Company's second integrated report prepared under the International Integrated Reporting Council (IIRC) framework. The report covers operations across Zydus Lifesciences Limited, its subsidiaries, and 118 operational units globally, offering a comprehensive view of financial, operational, and sustainability performance.

Record Financial Performance in FY2025-26

The Company delivered its strongest financial results to date, driven by sustained momentum across core businesses and contributions from strategic acquisitions. The following table summarises key consolidated financial metrics:

North America Formulations remained the largest business segment, contributing 44% of total revenues, with revenues rising to ₹1,16,820 million from ₹1,10,500 million in FY2024-25. India Formulations, the second-largest contributor at 25% of revenues, grew 11% to ₹65,740 million. International Markets Formulations delivered 40% growth, reaching ₹30,700 million. The Consumer Wellness business recorded 46% growth, reaching ₹39,134 million, driven primarily by the acquisition of Comfort Click Limited. The MedTech business recorded revenues of ₹7,823 million, accounting for 3% of total revenues.

Strategic Acquisitions and Business Expansion

FY2025-26 was marked by several significant inorganic initiatives that expanded the Company's global footprint across pharmaceuticals, biologics, MedTech, and consumer wellness.

The Company also received CE Mark approval for Andy, its proprietary robotic surgical platform, and entered into a partnership with Formycon AG to exclusively licence and commercialise FYB206, a biosimilar of Keytruda (Pembrolizumab), in the US and Canada.

Innovation and R&D Milestones

The Company's R&D engine continued to advance across novel chemical entities (NCEs), biosimilars, vaccines, and complex generics. Key milestones during FY2025-26 included:

• Saroglitazar Magnesium (PBC): Completed EPICS-III Phase 2(b)/3 clinical trial and filed a New Drug Application (NDA) with the USFDA for Primary Biliary Cholangitis.
• Zycubo (Copper Histidinate): Received final USFDA approval as the first and only approved therapy for Menkes disease, an ultra-rare condition.
• Tishtha: Launched the world's first biosimilar of Nivolumab, strengthening the Company's immuno-oncology presence.
• Anyra: Launched India's first indigenously developed biosimilar of Aflibercept.
• Usnoflast (ZYIL1): Ongoing Phase 2(b) clinical evaluation in the United States for Amyotrophic Lateral Sclerosis (ALS); holds Orphan Drug Designation and Fast Track Designation from the USFDA.
• Desidustat (Oxemia): Received marketing approval from the NMPA of China for renal anaemia treatment; has positively impacted over 1 lakh patient lives in India since launch.
• Zintrodiazine: Received approval from the DCGI to initiate two Phase III clinical trials in India for uncomplicated malaria.
• Measles-Rubella Vaccine: Commenced supply under the Government of India's Universal Immunisation Programme.

During the year, the Company filed 30 Abbreviated New Drug Applications (ANDAs) with the USFDA, taking cumulative filings to 508, and received 26 new product approvals. Cumulative ANDA approvals stood at 435. The Company also filed 142 patents during the year, with 19 granted.

Sustainability and ESG Performance

The Company continued to advance its ESG commitments across environmental, social, and governance dimensions. Renewable energy contributed 42% of the overall energy mix, and greenhouse gas intensity declined by 19% over the past two years. Total GHG emissions reduced in FY2025-26 stood at 1,40,665 tCO2e. The Company recycled 9,53,161 kilolitres of wastewater and saved 1,83,000 kilolitres of freshwater during the year. A recharge potential of 30 lakh kilolitres was created through rainwater harvesting structures, surpassing the target of 19 lakh kilolitres.

On the social front, the Zydus Medical College and Hospital in Dahod provides free healthcare to more than four lakh underserved patients annually. Total direct CSR beneficiaries stood at 4,65,523 for the reporting year. The Company's CSR expenditure for FY2025-26 was ₹101 million against a total obligation of ₹548 million, with ₹447.51 million transferred to the Unspent CSR Account for ongoing projects, primarily the establishment of Zydus Lifesciences University in Gujarat.

AGM and Dividend Details

The Thirty First Annual General Meeting is scheduled for Tuesday, August 11, 2026, at 10:00 a.m. (IST) through Video Conferencing/Other Audio Visual Means. The Board has recommended a final dividend of ₹1/- (Rupee One only) per equity share of ₹1/- each for FY2025-26, subject to shareholder approval. The record date for dividend entitlement is Friday, July 24, 2026, and the dividend payment date is on or around Friday, August 14, 2026.

The Board also approved a share buyback of up to ₹11,000 million at ₹1,150 per share, involving 9,565,217 equity shares, through the tender offer route. The Dividend Payout Ratio (including proposed dividend and buyback) for FY2025-26 is 23.82% of consolidated profits. The Company maintained its CRISIL AAA/Stable long-term rating and CRISIL A1+ short-term rating, reaffirmed during the year.

Zydus Lifesciences Limited has scheduled its 31st Annual General Meeting for August 11, 2026, at 10:00 a.m. IST via Video Conferencing. The meeting will transact business through electronic voting only, with remote e-voting commencing on August 8, 2026, and concluding on August 10, 2026. The record date to determine member entitlement for the dividend for the financial year ended March 31, 2026, is Friday, July 24, 2026.

E-Voting and Shareholder Participation

The company has appointed Mr. Ashish Doshi, Practicing Company Secretary, as the Scrutinizer to ensure the fair conduct of remote e-voting and e-voting during the AGM. Shareholders holding shares in physical or dematerialized mode as of the cut-off date, Tuesday, August 4, 2026, are eligible to vote. Members who have cast their vote via remote e-voting may participate in the AGM through VC/OAVM but are not entitled to vote again during the meeting.

Corporate Calendar

The Integrated Annual Report for FY2025-26 was sent electronically to members on July 10, 2026. Shareholders holding physical shares are requested to update their KYC details and email addresses with the Registrar and Share Transfer Agent to ensure seamless communication and dividend receipt.